Adult Diffuse Low-Grade Gliomas: 35-Year Experience at the Nancy France Neurooncology Unit.
chemotherapy
diffuse low-grade glioma
prognosis
quality of life
radiation therapy
surgery
survival
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
20
06
2020
accepted:
20
08
2020
entrez:
16
11
2020
pubmed:
17
11
2020
medline:
17
11
2020
Statut:
epublish
Résumé
To report survival, spontaneous prognostic factors, and treatment efficacy in a French monocentric cohort of diffuse low-grade glioma (DLGG) patients over 35 years of follow-up. A monocentric retrospective study of 339 patients diagnosed with a new DLGG between 01/01/1982 and 01/01/2017 was created. Inclusion criteria were patient age ≥18 years at diagnosis and histological diagnosis of WHO grade II glioma (according to 1993, 2007, and 2016 WHO classifications). The survival parameters were estimated using the Kaplan-Meier method with a 95% confidence interval. Differences in survival were tested for statistical significance by the log-rank test. Factors were considered significant when A total of 339 patients were included with a median follow-up of 8.7 years. The Kaplan-Meier median overall survival was 15.7 years. At the time of radiological diagnosis, Karnofsky Performance Status score and initial tumor volume were significant independent prognostic factors. Oncological prognostic factors were the extent of resection for patients who underwent surgery and the timing of radiotherapy for those concerned. In this study, patients who had delayed radiotherapy (provided remaining low grade) did not have worse survival compared with patients who had early radiotherapy. The functional capabilities of the patients were preserved enough so that they could remain independent during at least three quarters of the follow-up. This large monocentric series spread over a long time clarifies the effects of different therapeutic strategies and their combination in the management of DLGG.
Sections du résumé
BACKGROUND
BACKGROUND
To report survival, spontaneous prognostic factors, and treatment efficacy in a French monocentric cohort of diffuse low-grade glioma (DLGG) patients over 35 years of follow-up.
METHODS
METHODS
A monocentric retrospective study of 339 patients diagnosed with a new DLGG between 01/01/1982 and 01/01/2017 was created. Inclusion criteria were patient age ≥18 years at diagnosis and histological diagnosis of WHO grade II glioma (according to 1993, 2007, and 2016 WHO classifications). The survival parameters were estimated using the Kaplan-Meier method with a 95% confidence interval. Differences in survival were tested for statistical significance by the log-rank test. Factors were considered significant when
RESULTS
RESULTS
A total of 339 patients were included with a median follow-up of 8.7 years. The Kaplan-Meier median overall survival was 15.7 years. At the time of radiological diagnosis, Karnofsky Performance Status score and initial tumor volume were significant independent prognostic factors. Oncological prognostic factors were the extent of resection for patients who underwent surgery and the timing of radiotherapy for those concerned. In this study, patients who had delayed radiotherapy (provided remaining low grade) did not have worse survival compared with patients who had early radiotherapy. The functional capabilities of the patients were preserved enough so that they could remain independent during at least three quarters of the follow-up.
CONCLUSION
CONCLUSIONS
This large monocentric series spread over a long time clarifies the effects of different therapeutic strategies and their combination in the management of DLGG.
Identifiants
pubmed: 33194684
doi: 10.3389/fonc.2020.574679
pmc: PMC7656991
doi:
Types de publication
Journal Article
Langues
eng
Pagination
574679Informations de copyright
Copyright © 2020 Obara, Blonski, Brzenczek, Mézières, Gaudeau, Pouget, Gauchotte, Verger, Vogin, Moureaux, Duffau, Rech and Taillandier.
Références
J Neurosurg Sci. 2015 Dec;59(4):351-60
pubmed: 26394241
J Neurol Neurosurg Psychiatry. 2005 Jun;76(6):845-51
pubmed: 15897509
N Engl J Med. 2016 Apr 7;374(14):1344-55
pubmed: 27050206
Acta Neurochir (Wien). 2016 Jan;158(1):51-8
pubmed: 26530708
Lancet. 2005 Sep 17-23;366(9490):985-90
pubmed: 16168780
PLoS One. 2018 Sep 20;13(9):e0203639
pubmed: 30235224
World Neurosurg. 2014 Jul-Aug;82(1-2):e129-31
pubmed: 24636936
J Neurosurg. 2001 Nov;95(5):735-45
pubmed: 11702861
Clin Neurol Neurosurg. 2013 Dec;115(12):2508-13
pubmed: 24225484
Oncotarget. 2018 Sep 14;9(72):33623-33633
pubmed: 30263090
Cancer. 1994 Sep 15;74(6):1784-91
pubmed: 8082081
Clin Neurol Neurosurg. 2012 Oct;114(8):1135-44
pubmed: 22425370
Cochrane Database Syst Rev. 2014 May 15;(5):CD007104
pubmed: 24833028
Acta Neuropathol. 2018 Apr;135(4):601-615
pubmed: 29368212
J Clin Oncol. 2002 Apr 15;20(8):2076-84
pubmed: 11956268
Lancet Oncol. 2016 Nov;17(11):1521-1532
pubmed: 27686946
World Neurosurg. 2018 Dec;120:e762-e775
pubmed: 30172972
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
Ann Oncol. 2017 Aug 1;28(8):1942-1948
pubmed: 28475680
J Neurooncol. 2015 Dec;125(3):503-30
pubmed: 26530265
Neuro Oncol. 2017 Feb 1;19(2):242-251
pubmed: 27571885
Curr Oncol. 2018 Feb;25(1):e33-e39
pubmed: 29507493
Am J Clin Oncol. 2013 Dec;36(6):612-9
pubmed: 22892428
World Neurosurg. 2019 Jan 23;:
pubmed: 30684706
Neurology. 2000 Apr 11;54(7):1442-8
pubmed: 10751254
Brain Pathol. 1993 Jul;3(3):255-68
pubmed: 8293185
Expert Opin Drug Saf. 2009 Jul;8(4):493-9
pubmed: 19435405
J Neurosurg. 2003 Nov;99(5):854-62
pubmed: 14609165
J Clin Neurosci. 2018 Dec;58:124-129
pubmed: 30287250
Neurosurgery. 2012 Sep;71(3):729-39; discussion 739-40
pubmed: 22668885
J Neurooncol. 2015 Dec;125(3):551-83
pubmed: 26530266
J Neurooncol. 2012 Jun;108(2):309-18
pubmed: 22362370
Neuro Oncol. 2009 Aug;11(4):437-45
pubmed: 19018039
J Clin Oncol. 2012 Jul 10;30(20):2559-65
pubmed: 22529254
J Neurooncol. 2019 Oct;145(1):115-123
pubmed: 31556015
Am J Pathol. 2010 Dec;177(6):2708-14
pubmed: 21075857
Neuro Oncol. 2015 Mar;17(3):332-42
pubmed: 25087230
Neuro Oncol. 2009 Apr;11(2):176-82
pubmed: 18697954
BMC Cancer. 2018 Jan 6;18(1):48
pubmed: 29306321
Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):218-24
pubmed: 21549518
Crit Rev Oncol Hematol. 2018 Feb;122:83-91
pubmed: 29458793
Acta Neurochir (Wien). 2012 Apr;154(4):569-74
pubmed: 22278663
Annu Int Conf IEEE Eng Med Biol Soc. 2016 Aug;2016:4403-4406
pubmed: 28269254
CNS Oncol. 2015;4(5):341-6
pubmed: 26544062
Cancer. 2009 Sep 1;115(17):3969-78
pubmed: 19536875
J Neurooncol. 1997 Aug;34(1):85-101
pubmed: 9210055
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Curr Treat Options Neurol. 2014 Apr;16(4):284
pubmed: 24595756
Cochrane Database Syst Rev. 2015 Jun 29;(6):CD009229
pubmed: 26118544
Neuroimage. 2011 Jun 1;56(3):992-1000
pubmed: 21414413
Neurology. 2018 Oct 2;91(14):657-662
pubmed: 30158156
Neurooncol Pract. 2019 Mar;6(2):124-133
pubmed: 30949360